Global X S&P Biotech ETF
Performance
Total return to 23 Oct 2026, distributions reinvested, before franking. ASX figures are to 30 Sept 2026 and gross of franking, so they run higher for franked Australian funds.
What it costs to hold
Management fee plus trading costs, compared with similar funds.
A typical fund among Global ex-Australia equity funds would cost $296 (0.59% a year), so CURE is $36 cheaper.
Spread is the average gap between buying and selling prices on the ASX. Fees are shown on a flat balance, not compounded on growth. Excludes tax and any adviser or platform fees.
Calendar-year returns
Where the money is
Look-through exposure as at 2 Sept 2026 · 146 securities · top 10 = 15.6%
Country
Monthly returns
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −0.5 | −2.0 | −1.9 | 2.3 | 5.9 | 22.5 | −6.3 | 5.0 | 0.2 | −5.4 | 18.3YTD | ||
| 2025 | 3.2 | −6.9 | −4.5 | −5.3 | −1.3 | 2.2 | 4.4 | 4.0 | 9.2 | 12.6 | 10.7 | −3.3 | 25.3 |
| 2024 | 2.7 | 14.0 | −7.2 | −10.2 | 2.0 | 5.1 | 9.0 | −3.1 | −4.2 | 5.7 | 2.4 | −5.6 | 8.1 |
| 2023 | 2.2 | −1.3 | −8.5 | 6.5 | 7.0 | −1.4 | −0.7 | −1.3 | −7.2 | −10.6 | 9.8 | 19.4 | 10.6 |
| 2022 | −18.7 | −3.3 | −1.7 | −11.4 | −7.1 | 7.9 | 9.6 | 3.1 | −0.1 | 7.3 | −7.8 | 0.6 | −23.0 |
| 2021 | 3.8 | −4.5 | −8.2 | 2.9 | −5.9 | 8.6 | −6.7 | 7.1 | −3.3 | −4.1 | −3.7 | −2.9 | −17.1 |
| 2020 | 0.0 | −3.7 | −2.7 | 17.6 | 3.3 | 4.3 | −3.4 | −4.2 | 5.1 | 2.8 | 10.3 | 5.6 | 38.3 |
| 2019 | 12.6 | 11.0 | 1.4 | −3.1 | −5.8 | 6.4 | 0.6 | −1.7 | −6.2 | 3.3 | 16.1 | −0.9 | 35.6 |
| 2018 | −9.7 | −9.7 |
Total return each month in %, distributions reinvested, before franking. The latest month runs to the last price date. The first year starts from listing.
Top holdings
Most similar funds
Overlap is the share of the portfolio held in common, look-through. Correlation is of daily returns. High overlap means close substitutes.
CURE questions answered
Written from the latest data on this page. General information only, not financial advice.
How diversified is Global X S&P Biotech ETF?
Global X S&P Biotech ETF holds 146 securities, and its ten largest positions make up 15.6% of the fund, more spread out than the 36.4% typical of Global ex-Australia equity funds. That makes it moderately diversified.
Its country exposure is almost entirely United States (100.0%), based on holdings as at 2 Sept 2026.
Which ETFs does CURE double up with most?
No other ASX fund shares more than 10% of its holdings with CURE, and no fund's returns track it closely, so it offers a fairly distinct exposure.
How is Global X S&P Biotech ETF managed – active or passive?
Global X S&P Biotech ETF is passively managed: it follows an index and holds what that index holds, rather than relying on a manager's stock picks.
Among Global ex-Australia equity funds, active funds charge a median 0.75% a year and index funds 0.45%.
What will I pay in fees for CURE?
CURE charges a management fee of 0.45% a year, about $45 for every $10,000 invested. Only 46% of the 471 ASX ETFs we track charge more, and the median fee is 0.44%. Among Global ex-Australia equity funds, the median is 0.55%.
Lower-cost funds with a similar focus include iShares Global Healthcare ETF (IXJ) at 0.41%.
The fee is taken from the fund's assets and is already reflected in its returns. You'll also pay brokerage when you buy or sell, and the bid-ask spread, which has averaged 0.35% for CURE.
Does Global X S&P Biotech ETF follow a theme?
Yes. Global X S&P Biotech ETF focuses on healthcare. Thematic funds are narrower than the broad market, so they can rise or fall much more than it does.
Other ASX funds with a healthcare focus include iShares Global Healthcare ETF (IXJ), Betashares Global Healthcare ETF - Currency Hedged (DRUG) and VanEck Global Healthcare Leaders ETF (HLTH).
What is under the hood of CURE?
As at 2 Sept 2026, CURE's ten largest holdings are Moderna Inc (3.0%), Twist Bioscience (1.8%), Halozyme Therape (1.4%), Kymera Therapeut (1.4%), Natera Inc (1.4%), Praxis Precision (1.4%), Revolution Medic (1.3%), Travere Therapeu (1.3%), Oruka Therapeuti (1.3%) and Regeneron Pharm (1.3%). Together they make up 15.6% of the fund.
It follows an index; the issuer's PDS sets out how that index chooses and weights its holdings. Its top 10 weighting of 15.6% compares with 36.4% for Global ex-Australia equity funds.
How well has Global X S&P Biotech ETF performed?
Based on its category, Global X S&P Biotech ETF aims to grow your capital in line with the index it tracks.
To 23 Oct 2026, with distributions reinvested, it returned 30.5% over 1 year (median 6.3%; ranked 5 of 121), 26.5% a year over 3 years (median 16.5% a year; ranked 7 of 82) and 5.2% a year over 5 years (median 9.4% a year; ranked 58 of 66). The medians and rankings compare it with Global ex-Australia equity funds. Since listing in 2018 it has returned 7.9% a year.
Tracking difference is the gap between a fund's return and its index's return. We don't hold index returns, so we can't measure it for CURE; the issuer reports it in the monthly fact sheet. As a guide, a well-run index fund trails its index by about its fee, here 0.45% a year, and a much bigger gap is a warning sign.
Past performance is not a reliable indicator of future performance.